YOLFTbeta
Medicure Inc

Medicure Inc

MPH · V · Healthcare / Drug Manufacturers - Specialty & Generic

3.70CAD-0.30 (-7.50%)

Price History

Full chart

Market Stats

Previous Close4.00
Open4.00
Day Range3.70 – 4.00
52-Week Range0.85 – 2.99
Volume4.72K
Market Cap30.47M
P/E (TTM)0.00
Forward P/E13.48
EPS-0.72
Dividend Yield0.00%
Beta1.27
50-Day Avg1.93
200-Day Avg1.34

About

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Albert David Friesen Ph.D.
  • Employees0
  • Headquarters2-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6, Canada
  • Websitehttps://www.medicure.com

Leadership

  • Dr. Albert David Friesen Ph.D.Founder, CEO, President & Chairman of the Board · b. 1947
  • Mr. James F. Kinley C.A., CPAInterim CFO & Director · b. 1978
  • Dr. Reuben Saba Ph.D.Vice President of Scientific & Medical Affairs

Financials

Income Statement

Currency: CAD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue135.87K183.91K241.28K445.46K459.20K299.74K5.94M2.25M4.79M3.32M3.63M4.80M2.60M5.05M9.02M22.08M37.78M27.13M29.11M20.17M11.61M21.74M23.07M21.69M21.91M28.86M
Growth (%)-+35.36%+31.19%+84.62%+3.08%-34.73%+1883.32%-62.20%+113.27%-30.79%+9.38%+32.21%-45.74%+94.06%+78.68%+144.70%+71.07%-28.18%+7.28%-30.70%-42.45%+87.29%+6.08%-5.94%+0.98%+31.72%
Cost of Revenue------387.80K605.62K377.08K571.69K673.52K1.07M665.90K868.12K1.03M2.26M9.77M3.46M4.15M7.27M6.48M9.03M6.99M8.14M8.82M17.11M
Gross Profit135.87K183.91K241.28K445.46K459.20K299.74K5.56M1.64M4.42M2.75M2.95M3.73M1.94M4.18M8.00M19.82M28.01M23.67M24.96M12.90M5.13M12.71M16.07M13.56M13.09M11.75M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%93.48%73.05%92.13%82.77%81.44%77.71%74.42%82.81%88.59%89.77%74.14%87.23%85.74%63.95%44.19%58.46%69.69%62.48%59.75%40.71%
Operating Expense3.37M4.06M4.43M6.43M15.88M13.18M36.67M43.39M11.41M6.25M4.20M3.72M4.02M4.02M6.88M15.10M21.33M20.02M26.18M23.63M12.42M13.29M14.77M14.41M15.83M18.64M
Operating Income-3.23M-3.88M-4.19M-5.99M-15.42M-12.89M-31.12M-41.74M-6.99M-3.50M-1.25M10.09K-2.09M164.42K1.11M4.72M6.68M3.65M-1.23M-10.73M-7.29M-574.00K1.31M-854.00K-2.74M-6.89M
Operating Margin-2378.79%-2107.03%-1738.09%-1344.47%-3357.87%-4298.81%-523.41%-1857.66%-145.88%-105.66%-34.38%0.21%-80.17%3.26%12.33%21.38%17.69%13.46%-4.21%-53.18%-62.76%-2.64%5.68%-3.94%-12.49%-23.87%
EBITDA-3.21M-3.81M-4.16M-5.95M-15.36M-12.58M-28.40M-25.79M-904.99K-2.29M-67.62K887.64K-1.62M-623.64K1.86M1.62M6.79M11.84M-1.34M-8.80M-4.51M2.57M3.37M1.32M1.54M-4.19M
EBITDA Margin-2365.94%-2074.13%-1724.36%-1335.26%-3345.27%-4196.11%-477.65%-1147.53%-18.88%-69.15%-1.86%18.50%-62.33%-12.35%20.56%7.34%17.98%43.63%-4.60%-43.65%-38.88%11.82%14.59%6.07%7.03%-14.53%
Net Income-3.23M-3.88M-4.19M-5.99M-14.87M-12.61M-31.70M-57.40M-13.32M-5.53M-2.01M23.39M-2.57M-1.64M2.05M1.67M27.66M43.42M3.93M-19.79M-6.84M-727.00K1.36M-922.00K-1.04M-7.10M
Net Income Margin-2378.79%-2107.03%-1738.09%-1344.47%-3237.37%-4206.05%-533.30%-2554.48%-277.85%-166.79%-55.51%487.53%-98.91%-32.45%22.71%7.56%73.21%160.03%13.49%-98.08%-58.96%-3.34%5.92%-4.25%-4.74%-24.60%
R&D2.48M3.05M3.12M4.28M13.56M10.22M23.34M28.66M22.71K393.38K204.69K1.04M1.70M688.67K1.34M4.87M5.09M5.15M6.68M4.35M3.30M1.80M2.75M2.41M3.08M3.18M
R&D as % of Total Revenue1821.91%1657.82%1292.11%960.50%2953.87%3409.33%392.55%1275.42%0.47%11.86%5.64%21.77%65.34%13.63%14.88%22.03%13.48%18.97%22.95%21.56%28.42%8.26%11.94%11.09%14.06%11.02%
Interest Expense------1.96M3.83M4.94M3.28M3.12M553.73K418.06K415.83K0367.27K1.15M89.92K022.00K49.00K38.00K23.00K20.00K10.00K51.00K
Interest Expense % of Total Revenue------32.94%170.48%103.18%98.87%86.06%11.54%16.06%8.23%0.00%1.66%3.03%0.33%0.00%0.11%0.42%0.17%0.10%0.09%0.05%0.18%

Balance Sheet

Currency: CAD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.42M9.38M5.30M22.39M10.07M38.81M59.79M34.81M9.55M5.97M5.17M4.74M3.42M3.61M6.56M21.26M214.73M128.93M103.76M42.28M34.05M28.41M29.90M28.06M29.68M24.95M
Total Liabilities570.08K389.66K353.91K817.57K2.73M1.64M25.48M41.36M29.10M30.93M32.07M6.56M7.75M9.48M10.47M16.80M175.77M48.22M20.17M15.34M14.91M10.00M8.89M8.16M8.90M12.04M
Total Equity3.85M8.99M4.94M21.57M7.34M37.17M34.31M-6.56M-19.55M-24.96M-26.89M-1.82M-4.33M-5.88M-3.91M4.46M36.87M80.71M83.59M26.94M19.15M18.41M21.00M19.90M20.78M12.91M
Cash3.78M8.34M4.13M19.95M7.59M34.92M31.77M11.90M1.98M371.26K750.18K1.12M126.61K234.30K493.87K3.57M12.27M5.26M24.14M12.96M2.72M3.69M4.86M6.37M7.19M3.83M
Total Debt------16.94M34.19M25.04M24.14M22.47M4.65M4.78M-4.88M4.24M72.78M--1.09M1.45M1.17M849.00K544.00K--
Net Debt-3.78M-8.34M-4.13M-19.95M-7.59M-34.92M-14.83M22.28M23.06M23.77M21.72M3.52M4.66M-4.39M674.19K60.51M-5.26M-24.14M-11.88M-1.27M-2.52M-4.01M-5.83M--

Cash Flow

Currency: CAD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.73M-4.17M-3.98M-6.15M-12.07M-12.68M-25.25M-41.86M-10.42M-1.45M477.48K417.29K-990.48K110.88K473.97K142.79K6.41M21.92M742.27K-14.64M-2.24M3.99M1.83M2.08M1.38M-560.00K
Investing Cash Flow--------------5.51K-41.00K-226.57K-42.18M54.15M19.66M34.28M-7.24M-2.69M----
Financing Cash Flow2.87M9.01M43.29K22.23M133.00K41.25M45.02M22.59M---51.53K-2.00K10.46K3.12M44.51M-82.97M-2.66M-30.26M-766.00K-316.00K-355.00K-297.00K-370.00K-415.00K
Capital Expenditure134.26K37.99K5.20K21.73K42.80K1.24M187.04K14.59K238.54K141.83K44.81K97.91K7.40K5.51K28.65K226.57K464.21K1.32M1.48M13.85M2.00K818.00K310.00K270.00K739.00K0
Free Cash Flow-2.86M-4.21M-3.99M-6.17M-12.11M-13.92M-25.43M-41.88M-10.66M-1.59M432.67K319.38K-997.88K105.37K445.32K-83.78K5.95M20.60M-735.76K-28.49M-2.24M3.17M1.52M1.81M638.00K-560.00K
FCF to OCF104.92%100.91%100.13%100.35%100.35%109.81%100.74%100.03%102.29%109.76%90.61%76.54%100.75%95.03%93.96%-58.67%92.76%93.97%-99.12%194.57%100.09%79.49%83.04%87.01%46.33%100.00%

Earnings

Report DateAug 31, 2002Nov 30, 2002Feb 28, 2003May 31, 2003Oct 23, 2003Jan 14, 2004Apr 22, 2004Aug 11, 2004Oct 14, 2004Jan 13, 2005Apr 5, 2005Aug 24, 2005Oct 13, 2005Jan 10, 2006Apr 13, 2006Aug 15, 2006Oct 12, 2006Jan 12, 2007Apr 12, 2007Aug 23, 2007Oct 15, 2007Jan 14, 2008Apr 14, 2008Oct 15, 2008Jan 13, 2009Apr 13, 2009Oct 14, 2009Jan 12, 2010Apr 13, 2010Sep 28, 2010Oct 13, 2010Jan 18, 2011Apr 12, 2011Aug 3, 2011Oct 12, 2011Jan 26, 2012Apr 20, 2012Aug 1, 2012Oct 17, 2012Jan 29, 2013Apr 30, 2013Oct 30, 2013Mar 26, 2014Sep 10, 2014Oct 16, 2014Apr 29, 2015Aug 11, 2015Nov 9, 2015Mar 31, 2016May 11, 2016Aug 10, 2016Nov 9, 2016Dec 31, 2016May 24, 2017Aug 7, 2017Nov 21, 2017May 23, 2018Aug 15, 2018Nov 20, 2018Dec 31, 2018May 27, 2019Aug 8, 2019Nov 26, 2019Dec 31, 2019May 12, 2020Aug 11, 2020Nov 11, 2020Apr 20, 2021Aug 27, 2021Nov 22, 2021May 30, 2022Aug 25, 2022Nov 24, 2022May 29, 2023Jul 28, 2023Nov 19, 2026
EPS Estimate-----0.45-0.45-0.30-0.45-0.60-0.60-0.90-1.05-1.20-0.60-0.60-0.45-0.45-0.52-0.94-1.20-1.80-1.87-1.35---------------------0.00-0.010.010.170.120.140.130.110.040.090.120.010.100.120.040.01-0.040.00-0.01-0.13-0.07----------
EPS Actual-0.49-0.48-0.37-0.30-0.30-0.45-0.30-0.45-0.60-0.75-0.90-1.05-0.90-0.75-0.60-0.45-0.45-0.90-1.20-1.95-1.95-1.95-2.55-0.35-0.80-0.42-0.22-0.02-0.24-0.15-0.200.080.10-0.222.250.14-0.03-0.13-0.02-0.04-0.09-0.040.01-0.060.100.010.03-0.030.040.050.030.120.33-0.330.080.080.080.09-0.030.09-0.18-0.06-0.04-0.30-0.140.00-0.10-0.41-0.06-0.090.19-0.070.110.040.02-
Surprise----33.33%0.00%0.00%0.00%0.00%-25.00%0.00%0.00%25.00%-25.00%0.00%0.00%0.00%-73.08%-27.66%-62.50%-8.33%-4.28%-88.89%-----------------------200.00%-400.00%-76.47%-58.33%-78.57%-7.69%200.00%-925.00%-11.11%-33.33%700.00%-10.00%-125.00%125.00%-1900.00%-50.00%--2875.00%-7.69%102.43%----------
Timing----Pre-market-After-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-marketPre-market-Pre-marketAfter-hours----------------------After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours--After-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap30.47M
Enterprise Value26.31M
Trailing P/E0.00
Forward P/E13.48
PEG Ratio0.17
Price / Sales0.95
Price / Book2.37
EPS-0.72
Book Value1.11
Revenue (TTM)32.08M
Gross Profit (TTM)12.19M
EBITDA-5.62M
Profit Margin-23.23%
Operating Margin-18.22%
Return on Equity-49.88%
Return on Assets-17.78%
Shares Outstanding10.44M
Shares Float5.22M
Beta1.27
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 2, 20121:15